Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.

Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM.

Mol Cancer Ther. 2018 Jun 11. pii: molcanther.1194.2017. doi: 10.1158/1535-7163.MCT-17-1194. [Epub ahead of print]

PMID:
29891486
2.

Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers.

Leng S, Diergaarde B, Picchi MA, Wilson DO, Gilliland FD, Yuan JM, Siegfried JM, Belinsky SA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):187-196. doi: 10.1164/rccm.201708-1659OC.

PMID:
29437466
3.

Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.

Stabile LP, Farooqui M, Kanterewicz B, Abberbock S, Kurland BF, Diergaarde B, Siegfried JM.

J Thorac Oncol. 2018 Mar;13(3):399-412. doi: 10.1016/j.jtho.2017.11.126. Epub 2017 Dec 9.

PMID:
29233790
4.

Gene methylation biomarkers in sputum as a classifier for lung cancer risk.

Leng S, Wu G, Klinge DM, Thomas CL, Casas E, Picchi MA, Stidley CA, Lee SJ, Aisner S, Siegfried JM, Ramalingam S, Khuri FR, Karp DD, Belinsky SA.

Oncotarget. 2017 Jul 15;8(38):63978-63985. doi: 10.18632/oncotarget.19255. eCollection 2017 Sep 8.

5.

Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.

Korde A, Jin L, Zhang JG, Ramaswamy A, Hu B, Kolahian S, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1443-1455. doi: 10.1164/rccm.201610-2157OC.

PMID:
28853613
6.

Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.

Barón AE, Kako S, Feser WJ, Malinowski H, Merrick D, Garg K, Malkoski S, Pretzel S, Siegfried JM, Franklin WA, Miller Y, Wolf HJ, Varella-Garcia M.

J Thorac Oncol. 2017 Oct;12(10):1512-1523. doi: 10.1016/j.jtho.2017.06.008. Epub 2017 Jun 19.

7.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

PMID:
28472537
8.

Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.

Siegfried JM, Farooqui M, Rothenberger NJ, Dacic S, Stabile LP.

Oncotarget. 2017 Apr 11;8(15):24063-24076. doi: 10.18632/oncotarget.16030.

9.

Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Zhou J, Qu Z, Sun F, Han L, Li L, Yan S, Stabile LP, Chen LF, Siegfried JM, Xiao G.

Cancer Immunol Res. 2017 Mar;5(3):257-268. doi: 10.1158/2326-6066.CIR-16-0073. Epub 2017 Jan 20.

10.

A prospective and retrospective analysis of smoking behavior changes in ever smokers with high risk for lung cancer from New Mexico and Pennsylvania.

Leng S, Weissfeld JL, Picchi MA, Styn MA, Claus ED, Clark VP, Wu G, Thomas CL, Gilliland FD, Yuan J, Siegfried JM, Belinsky SA.

Int J Mol Epidemiol Genet. 2016 Jun 1;7(2):95-104. eCollection 2016.

11.

ATM protein is deficient in over 40% of lung adenocarcinomas.

Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, Siegfried JM, Conrads TP, Smith NR, O'Connor MJ, Pierce AJ, Bakkenist CJ.

Oncotarget. 2016 Sep 6;7(36):57714-57725. doi: 10.18632/oncotarget.9757.

12.

KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.

Gao W, Jin J, Yin J, Land S, Gaither-Davis A, Christie N, Luketich JD, Siegfried JM, Keohavong P.

Mol Carcinog. 2017 Feb;56(2):381-388. doi: 10.1002/mc.22501. Epub 2016 Jun 6.

PMID:
27182622
13.

Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.

Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP.

Neoplasia. 2015 Nov;17(11):817-25. doi: 10.1016/j.neo.2015.11.002.

14.

Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.

Beumer JH, Fu KY, Anyang BN, Siegfried JM, Bakkenist CJ.

BMC Cancer. 2015 Oct 5;15:649. doi: 10.1186/s12885-015-1649-3.

15.

Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions.

Weissfeld JL, Lin Y, Lin HM, Kurland BF, Wilson DO, Fuhrman CR, Pennathur A, Romkes M, Nukui T, Yuan JM, Siegfried JM, Diergaarde B.

J Thorac Oncol. 2015 Nov;10(11):1538-45. doi: 10.1097/JTO.0000000000000666.

16.

NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function.

Sun F, Qu Z, Xiao Y, Zhou J, Burns TF, Stabile LP, Siegfried JM, Xiao G.

Oncogene. 2016 May 5;35(18):2299-310. doi: 10.1038/onc.2015.299. Epub 2015 Aug 24.

17.

Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer.

Tessema M, Yingling CM, Picchi MA, Wu G, Liu Y, Weissfeld JL, Siegfried JM, Tesfaigzi Y, Belinsky SA.

J Thorac Oncol. 2015 Aug;10(8):1181-8. doi: 10.1097/JTO.0000000000000592.

18.

15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers.

Leng S, Liu Y, Weissfeld JL, Thomas CL, Han Y, Picchi MA, Edlund CK, Willink RP, Gaither Davis AL, Do KC, Nukui T, Zhang X, Burki EA, Van Den Berg D, Romkes M, Gauderman WJ, Crowell RE, Tesfaigzi Y, Stidley CA, Amos CI, Siegfried JM, Gilliland FD, Belinsky SA.

J Natl Cancer Inst. 2015 Feb 23;107(5). pii: djv035. doi: 10.1093/jnci/djv035.

19.

Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: results from the Pittsburgh Lung Screening Study.

Dixit R, Weissfeld JL, Wilson DO, Balogh P, Sufka P, Siegfried JM, Grandis JR, Diergaarde B.

Cancer. 2015 May 1;121(9):1431-5. doi: 10.1002/cncr.29189. Epub 2015 Jan 5.

20.

Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.

Yu G, Herazo-Maya JD, Nukui T, Romkes M, Parwani A, Juan-Guardela BM, Robertson J, Gauldie J, Siegfried JM, Kaminski N, Kass DJ.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):780-90. doi: 10.1164/rccm.201310-1903OC.

21.

Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Weissfeld JL, Diergaarde B, Nukui T, Buch S, Pennathur A, Socinski MA, Siegfried JM, Romkes M.

J Thorac Oncol. 2014 Sep;9(9):1264-71. doi: 10.1097/JTO.0000000000000262.

22.

Validation of a blood protein signature for non-small cell lung cancer.

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM.

Clin Proteomics. 2014 Aug 1;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.

23.

Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.

Stabile LP, Rothstein ME, Gubish CT, Cunningham DE, Lee N, Siegfried JM.

J Thorac Oncol. 2014 Sep;9(9):1285-93. doi: 10.1097/JTO.0000000000000245.

24.

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR.

Clin Cancer Res. 2014 Jun 15;20(12):3289-98. doi: 10.1158/1078-0432.CCR-13-3360. Epub 2014 Apr 11.

25.

Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.

Ng YK, Lee JY, Supko KM, Khan A, Torres SM, Berwick M, Ho J, Kirkwood JM, Siegfried JM, Stabile LP.

Melanoma Res. 2014 Jun;24(3):207-18. doi: 10.1097/CMR.0000000000000060.

26.

Estrongenic steroid hormones in lung cancer.

Siegfried JM, Stabile LP.

Semin Oncol. 2014 Feb;41(1):5-16. doi: 10.1053/j.seminoncol.2013.12.009. Epub 2013 Dec 12. Review.

27.

Smoking out reproductive hormone actions in lung cancer.

Siegfried JM.

Mol Cancer Res. 2014 Jan;12(1):24-31. doi: 10.1158/1541-7786.MCR-13-0580. Epub 2014 Jan 7. Review.

28.

RET rearrangements in lung adenocarcinoma and radiation.

Dacic S, Luvison A, Evdokimova V, Kelly L, Siegfried JM, Villaruz LC, Socinski MA, Nikiforov YE.

J Thorac Oncol. 2014 Jan;9(1):118-20. doi: 10.1097/JTO.0000000000000015.

29.

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH.

Eur J Cancer. 2014 Jan;50(2):302-8. doi: 10.1016/j.ejca.2013.10.006. Epub 2013 Nov 15.

30.

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A.

Anticancer Res. 2013 Oct;33(10):4475-81.

31.

Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors.

Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S, Dhir R, Nukui T, Romkes M, Weissfeld JL.

Cancer Epidemiol. 2013 Aug;37(4):518-22. doi: 10.1016/j.canep.2013.03.020. Epub 2013 Apr 23.

32.

The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.

Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, Dacic S.

Cancer. 2013 Jun 15;119(12):2268-74. doi: 10.1002/cncr.28039. Epub 2013 Mar 22.

33.

Computerized identification of airway wall in CT examinations using a 3D active surface evolution approach.

Gu S, Fuhrman C, Meng X, Siegfried JM, Gur D, Leader JK, Sciurba FC, Pu J.

Med Image Anal. 2013 Apr;17(3):283-96. doi: 10.1016/j.media.2012.11.003. Epub 2012 Nov 29.

34.

c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR.

Clin Cancer Res. 2013 Jan 15;19(2):380-92. doi: 10.1158/1078-0432.CCR-12-1555. Epub 2012 Dec 4. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3715. Thomas, Sufi [added].

35.

Optimal threshold in CT quantification of emphysema.

Wang Z, Gu S, Leader JK, Kundu S, Tedrow JR, Sciurba FC, Gur D, Siegfried JM, Pu J.

Eur Radiol. 2013 Apr;23(4):975-84. doi: 10.1007/s00330-012-2683-z. Epub 2012 Nov 1.

36.

Automated lobe-based airway labeling.

Gu S, Wang Z, Siegfried JM, Wilson D, Bigbee WL, Pu J.

Int J Biomed Imaging. 2012;2012:382806. doi: 10.1155/2012/382806. Epub 2012 Oct 9.

37.

Illustration of the obstacles in computerized lung segmentation using examples.

Meng X, Qiang Y, Zhu S, Fuhrman C, Siegfried JM, Pu J.

Med Phys. 2012 Aug;39(8):4984-91. doi: 10.1118/1.4737023.

38.

Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.

Stabile LP, Rothstein ME, Cunningham DE, Land SR, Dacic S, Keohavong P, Siegfried JM.

Carcinogenesis. 2012 Nov;33(11):2181-9. doi: 10.1093/carcin/bgs260. Epub 2012 Aug 2. Erratum in: Carcinogenesis. 2013 Jun;34(6):1411.

39.

Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers.

Flores KG, Stidley CA, Mackey AJ, Picchi MA, Stabler SP, Siegfried JM, Byers T, Berwick M, Belinsky SA, Leng S.

Carcinogenesis. 2012 Aug;33(8):1542-7. doi: 10.1093/carcin/bgs194. Epub 2012 Jun 4.

40.

CT based computerized identification and analysis of human airways: a review.

Pu J, Gu S, Liu S, Zhu S, Wilson D, Siegfried JM, Gur D.

Med Phys. 2012 May;39(5):2603-16. doi: 10.1118/1.4703901. Review.

41.

Anatomic segmentectomy for the solitary pulmonary nodule and early-stage lung cancer.

Schuchert MJ, Abbas G, Awais O, Pennathur A, Nason KS, Wilson DO, Siegfried JM, Luketich JD, Landreneau RJ.

Ann Thorac Surg. 2012 Jun;93(6):1780-5; discussion 1786-7. doi: 10.1016/j.athoracsur.2011.11.074. Epub 2012 Apr 6.

PMID:
22483652
42.

Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma.

Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR.

Head Neck. 2013 Feb;35(2):270-9. doi: 10.1002/hed.22963. Epub 2012 Mar 20.

43.

A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.

Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, Siegfried JM.

J Thorac Oncol. 2012 Apr;7(4):698-708. doi: 10.1097/JTO.0b013e31824ab6b0.

44.

Influence of age and IB status after resection of node-negative non-small cell lung cancer.

Schuchert MJ, Awais O, Abbas G, Horne ZD, Nason KS, Pennathur A, Souza AP, Siegfried JM, Wilson DO, Luketich JD, Landreneau RJ.

Ann Thorac Surg. 2012 Mar;93(3):929-35; discussion 935-6. doi: 10.1016/j.athoracsur.2011.09.047.

PMID:
22364984
45.

Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.

Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20.

46.

Serum biomarker profiles as diagnostic tools in lung cancer.

Nolen BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, Weissfeld JL, Wilson DO, Dacic S, Siegfried JM, Lokshin AE.

Cancer Biomark. 2011-2012;10(1):3-12. doi: 10.3233/CBM-2012-0229.

47.

Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.

Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM.

Respir Res. 2012 Feb 1;13:9. doi: 10.1186/1465-9921-13-9.

48.

Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP.

J Thorac Oncol. 2012 Mar;7(3):485-95. doi: 10.1097/JTO.0b013e31824177ea.

49.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.

Carr SR, Schuchert MJ, Pennathur A, Wilson DO, Siegfried JM, Luketich JD, Landreneau RJ.

J Thorac Cardiovasc Surg. 2012 Feb;143(2):390-7. doi: 10.1016/j.jtcvs.2011.10.023. Epub 2011 Dec 9.

50.

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA.

Oncogene. 2012 Sep 13;31(37):4107-16. doi: 10.1038/onc.2011.577. Epub 2011 Dec 12.

Supplemental Content

Loading ...
Support Center